肾细胞癌脉络丛转移患者的临床结局
单中心回顾性分析2003年1月至2019年1月治疗的19例患者共22个肾细胞癌脑室内转移灶,中位肿瘤体积2.2 cm³,19个转移灶初始接受放疗(16个立体定向体部放疗、3个全脑放疗),3个手术切除并辅助立体定向体部放疗;1年和3年无进展生存率分别为81.6%和68%,中位总生存2.8年,1年和5年总生存率分别为76.7%和28.3%,未观察到脑膜癌病,5例梗阻性脑积水患者均无需脑脊液分流。
要点
- 19例患者共22个肾细胞癌脑室内转移灶,中位肿瘤体积2.2 cm³。
- 19个转移灶初始放疗,3个手术切除并辅助立体定向体部放疗。
- 中位总生存2.8年,1年和5年总生存率分别为76.7%和28.3%。
核心结论
- 尽管该转移癌人群总生存相对有限,与当代脑实质转移队列相当,但采用局灶放疗和适形手术的模式在多数患者中实现了合理的局部中枢神经系统控制。
- 即使患者就诊时存在脑积水,也无需脑脊液分流。
研究设计与样本
- 单机构回顾性综述,纳入2003年1月至2019年1月治疗的肾细胞癌脑室内转移患者。
- 共识别19例患者中的22个肾细胞癌脑室内转移灶,随访61.3患者年。
- 采用容积分析 delineate 肿瘤大小,Kaplan-Meier 法评估生存数据。
主要发现
- 患者中位年龄64岁,中位肿瘤体积2.2 cm³。
- 19个转移灶初始接受放疗,其中16个接受立体定向体部放疗、3个接受全脑放疗;3个肿瘤手术切除并在 upfront 设置接受辅助立体定向体部放疗。
- 5例患者就诊时存在梗阻性脑积水,均无需脑脊液分流。
- 治疗后5个转移灶进展,1年和3年无进展生存率分别为81.6%和68%。
- 中位总生存2.8年,1年和5年总生存率分别为76.7%和28.3%;未观察到脑膜癌病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intraventricular metastatic brain tumors account for a small, but challenging, fraction of metastatic brain tumors (0.9%-4.5%). Metastases from renal cell carcinoma (RCC) account for a large portion of these intraventricular tumors. Although patient outcomes have been assumed to be poor, these have not been reported in a modern series with a multimodality treatment paradigm of radiotherapy (RT), resection, and cerebrospinal fluid (CSF) diversion. We have presented the first case series of patients with intraventricular metastatic tumors from RCC. METHODS: We performed a single-institution retrospective review of patients with intraventricular RCC metastases treated from January 2003 to January 2019. Volumetric analysis was used to delineate the tumor size and the Kaplan-Meier method to evaluate the survival data. RESULTS: A total of 22 intraventricular RCC metastases were identified in 19 patients with 61.3 patient-years of follow-up. The median patient age was 64 years, and the median tumor volume was 2.2 cm3. Overall, 19 metastases had been treated initially with RT. Of these, 16 had received stereotactic body RT and 3 had received whole brain RT. Three tumors were surgically excised and had received adjuvant stereotactic body RT in the upfront setting. Although 5 patients had presented with obstructive hydrocephalus, none had required CSF diversion. After treatment, 5 metastases had progressed, resulting in 1- and 3-year progression-free survival rates of 81.6% and 68%, respectively. The median overall survival was 2.8 years, with 1- and 5-year overall survival rates of 76.7% and 28.3%, respectively. Leptomeningeal carcinomatosis was not observed. CONCLUSIONS: Despite the relatively limited overall survival for this population with metastatic cancer, comparable to contemporary parenchymal brain metastasis cohorts, reasonable local central nervous system control was achieved in most patients using a paradigm of focal RT and resection, where indicated. Finally, CSF diversion was not required even in patients presenting with hydrocephalus.
引用
- Crisman CM, Patel AR, Winston G, et al. Clinical Outcomes in Patients with Renal Cell Carcinoma Metastases to the Choroid Plexus. World Neurosurg. 2020. PMID: 32251814. doi:10.1016/j.wneu.2020.03.125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。